Report Content
Chapter 1 Methodology
1.1 Methodology
1.2 Market definitions
1.3 Base estimates & working
1.4 Forecast calculations
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Autoimmune disease diagnostics industry 3600 synopsis, 2017 - 2030
2.1.1 Business trends
2.1.2 Disease type trends
2.1.3 Test type trends
2.1.4 End-use trends
2.1.5 Regional trends
Chapter 3 Autoimmune Disease Diagnostics Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2030
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 High incidence and prevalence of autoimmune diseases
3.3.1.2 Growing awareness about autoimmune diseases
3.3.1.3 Supportive government policies for research activities on autoimmune diseases
3.3.1.4 Technological advancements and increasing adoption of lab automation technologies
3.3.2 Industry pitfalls & challenges
3.3.2.1 Need for high capital investment in setting-up diagnosis centers
3.3.2.2 Slow turnaround time for test results and need for multiple diagnostic tests
3.4 Growth potential analysis
3.4.1 By disease type
3.4.2 By test type
3.4.3 By end-use
3.5 Covid-19 impact analysis
3.6 Porter’s analysis
3.7 Competitive landscape, 2021
3.7.1 Company matrix analysis, 2021
3.8 PESTEL analysis
Chapter 4 Autoimmune Disease Diagnostics Market, By Disease Type
4.1 Key segment trends
4.2 Systemic Autoimmune Disease
4.2.1 Market size, by region, 2017 - 2030 (USD Million)
4.2.2 Rheumatoid Arthritis
4.2.2.1 Market size, by region, 2017 - 2030 (USD Million)
4.2.3 Systemic Lupus Erythematosus
4.2.3.1 Market size, by region, 2017 - 2030 (USD Million)
4.2.4 Psoriasis
4.2.4.1 Market size, by region, 2017 - 2030 (USD Million)
4.2.5 Multiple Sclerosis
4.2.5.1 Market size, by region, 2017 - 2030 (USD Million)
4.2.6 Others
4.2.6.1 Market size, by region, 2017 - 2030 (USD Million)
4.3 Localized Autoimmune Disease
4.3.1 Market size, by region, 2017 - 2030 (USD Million)
4.3.2 Inflammatory Bowel Disease
4.3.2.1 Market size, by region, 2017 - 2030 (USD Million)
4.3.2.2 Type 1 Diabetes
4.3.2.2.1 Market size, by region, 2017 - 2030 (USD Million)
4.3.2.3 Thyroid
4.3.2.3.1 Market size, by region, 2017 - 2030 (USD Million)
4.3.2.4 Others
4.3.2.4.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 5 Autoimmune Disease Diagnostics Market, By Test Type
5.1 Key segment trends
5.2 Antinuclear Antibody Tests
5.2.1 Market size, by region, 2017 - 2030 (USD Million)
5.3 Autoantibody Tests
5.3.1 Market size, by region, 2017 - 2030 (USD Million)
5.4 C-reactive Protein (CRP)
5.4.1 Market size, by region, 2017 - 2030 (USD Million)
5.5 Complete Blood Count (CBC)
5.5.1 Market size, by region, 2017 - 2030 (USD Million)
5.6 Urinalysis
5.6.1 Market size, by region, 2017 - 2030 (USD Million)
5.7 Others
5.7.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 6 Autoimmune Disease Diagnostics Market, By End-use
6.1 Key segment trends
6.2 Hospitals
6.2.1 Market size, by region, 2017 - 2030 (USD Million)
6.3 Diagnostics Centers
6.3.1 Market size, by region, 2017 - 2030 (USD Million)
6.4 Others
6.4.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 7 Autoimmune Disease Diagnostics Market, By Region
7.1 Key regional trends
7.2 North America
7.2.1 Market size, by country, 2017-2030 (USD Million)
7.2.2 Market size, by disease type, 2017-2030 (USD Million)
7.2.2.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.2.2.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.2.3 Market size, by test type, 2017-2030 (USD Million)
7.2.4 Market size, by end-use, 2017-2030 (USD Million)
7.2.5 U.S.
7.2.5.1 Market size , by disease type, 2017-2030 (USD Million)
7.2.5.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.2.5.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.2.5.2 Market size, by test type, 2017-2030 (USD Million)
7.2.5.3 Market size, by end-use, 2017-2030 (USD Million)
7.2.6 Canada
7.2.6.1 Market size , by disease type, 2017-2030 (USD Million)
7.2.6.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.2.6.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.2.6.2 Market size, by test type, 2017-2030 (USD Million)
7.2.6.3 Market size, by end-use, 2017-2030 (USD Million)
7.3 Europe
7.3.1 Market size, by country, 2017-2030 (USD Million)
7.3.2 Market size, by disease type, 2017-2030 (USD Million)
7.3.2.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.3.2.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.3.3 Market size, by test type, 2017-2030 (USD Million)
7.3.4 Market size, by end-use, 2017-2030 (USD Million)
7.3.5 Germany
7.3.5.1 Market size , by disease type, 2017-2030 (USD Million)
7.3.5.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.3.5.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.3.5.2 Market size, by test type, 2017-2030 (USD Million)
7.3.5.3 Market size, by end-use, 2017-2030 (USD Million)
7.3.6 UK
7.3.6.1 Market size , by disease type, 2017-2030 (USD Million)
7.3.6.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.3.6.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.3.6.2 Market size, by test type, 2017-2030 (USD Million)
7.3.6.3 Market size, by end-use, 2017-2030 (USD Million)
7.3.7 France
7.3.7.1 Market size , by disease type, 2017-2030 (USD Million)
7.3.7.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.3.7.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.3.7.2 Market size, by test type, 2017-2030 (USD Million)
7.3.7.3 Market size, by end-use, 2017-2030 (USD Million)
7.3.8 Spain
7.3.8.1 Market size , by disease type, 2017-2030 (USD Million)
7.3.8.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.3.8.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.3.8.2 Market size, by test type, 2017-2030 (USD Million)
7.3.8.3 Market size, by end-use, 2017-2030 (USD Million)
7.3.9 Italy
7.3.9.1 Market size , by disease type, 2017-2030 (USD Million)
7.3.9.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.3.9.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.3.9.2 Market size, by test type, 2017-2030 (USD Million)
7.3.9.3 Market size, by end-use, 2017-2030 (USD Million)
7.4 Asia Pacific
7.4.1 Market size, by country, 2017-2030 (USD Million)
7.4.2 Market size, by disease type, 2017-2030 (USD Million)
7.4.2.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.4.2.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.4.3 Market size, by test type, 2017-2030 (USD Million)
7.4.4 Market size, by end-use, 2017-2030 (USD Million)
7.4.5 China
7.4.5.1 Market size , by disease type, 2017-2030 (USD Million)
7.4.5.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.4.5.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.4.5.2 Market size, by test type, 2017-2030 (USD Million)
7.4.5.3 Market size, by end-use, 2017-2030 (USD Million)
7.4.6 Japan
7.4.6.1 Market size , by disease type, 2017-2030 (USD Million)
7.4.6.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.4.6.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.4.6.2 Market size, by test type, 2017-2030 (USD Million)
7.4.6.3 Market size, by end-use, 2017-2030 (USD Million)
7.4.7 India
7.4.7.1 Market size , by disease type, 2017-2030 (USD Million)
7.4.7.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.4.7.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.4.7.2 Market size, by test type, 2017-2030 (USD Million)
7.4.7.3 Market size, by end-use, 2017-2030 (USD Million)
7.4.8 Australia
7.4.8.1 Market size , by disease type, 2017-2030 (USD Million)
7.4.8.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.4.8.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.4.8.2 Market size, by test type, 2017-2030 (USD Million)
7.4.8.3 Market size, by end-use, 2017 – 2028 (USD Million)
7.4.9 South Korea
7.4.9.1 Market size , by disease type, 2017-2030 (USD Million)
7.4.9.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.4.9.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.4.9.2 Market size, by test type, 2017-2030 (USD Million)
7.4.9.3 Market size, by end-use, 2017-2030 (USD Million)
7.5 Latin America
7.5.1 Market size, by country, 2017-2030 (USD Million)
7.5.2 Market size, by disease type, 2017-2030 (USD Million)
7.5.2.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.5.2.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.5.3 Market size, by test type, 2017-2030 (USD Million)
7.5.4 Market size, by end-use, 2017-2030 (USD Million)
7.5.5 Brazil
7.5.5.1 Market size , by disease type, 2017-2030 (USD Million)
7.5.5.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.5.5.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.5.5.2 Market size, by test type, 2017-2030 (USD Million)
7.5.5.3 Market size, by end-use, 2017-2030 (USD Million)
7.5.6 Mexico
7.5.6.1 Market size , by disease type, 2017-2030 (USD Million)
7.5.6.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.5.6.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.5.6.2 Market size, by test type, 2017-2030 (USD Million)
7.5.6.3 Market size, by end-use, 2017-2030 (USD Million)
7.5.7 Argentina
7.5.7.1 Market size , by disease type, 2017-2030 (USD Million)
7.5.7.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.5.7.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.5.7.2 Market size, by test type, 2017-2030 (USD Million)
7.5.7.3 Market size, by end-use, 2017-2030 (USD Million)
7.6 Middle East & Africa
7.6.1 Market size, by country, 2017-2030 (USD Million)
7.6.2 Market size, by disease type, 2017-2030 (USD Million)
7.6.2.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.6.2.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.6.3 Market size, by test type, 2017-2030 (USD Million)
7.6.4 Market size, by end-use, 2017-2030 (USD Million)
7.6.5 South Africa
7.6.5.1 Market size , by disease type, 2017-2030 (USD Million)
7.6.5.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.6.5.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.6.5.2 Market size, by test type, 2017-2030 (USD Million)
7.6.5.3 Market size, by end-use, 2017-2030 (USD Million)
7.6.6 Saudi Arabia
7.6.6.1 Market size , by disease type, 2017-2030 (USD Million)
7.6.6.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.6.6.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.6.6.2 Market size, by test type, 2017-2030 (USD Million)
7.6.6.3 Market size, by end-use, 2017 – 2030 (USD Million)
7.6.7 UAE
7.6.7.1 Market size , by disease type, 2017-2030 (USD Million)
7.6.7.1.1 Market size, by systemic autoimmune disease, 2017-2030 (USD Million)
7.6.7.1.2 Market size, by localized autoimmune disease, 2017-2030 (USD Million)
7.6.7.2 Market size, by test type, 2017-2030 (USD Million)
7.6.7.3 Market size, by end-use, 2017-2030 (USD Million)
Chapter 8 Company Profiles
8.1 Competitive dashboard, 2021
8.2 Abbott Laboratories
8.2.1 Business overview
8.2.2 Financial data
8.2.3 Product landscape
8.2.4 Strategic outlook
8.2.5 SWOT analysis
8.3 Bio-rad Laboratories
8.3.1 Business overview
8.3.2 Financial data
8.3.3 Product landscape
8.3.4 Strategic outlook
8.3.5 SWOT analysis
8.4 F. Hoffmann-la Roche
8.4.1 Business overview
8.4.2 Financial data
8.4.3 Product landscape
8.4.4 Strategic outlook
8.4.5 SWOT analysis
8.5 Thermo Fisher Scientific
8.5.1 Business overview
8.5.2 Financial data
8.5.3 Product landscape
8.5.4 Strategic outlook
8.5.5 SWOT analysis
8.6 Myriad Genetics
8.6.1 Business overview
8.6.2 Financial data
8.6.3 Product landscape
8.6.4 Strategic outlook
8.6.5 SWOT analysis
8.7 Euroimmun AG (Perkin Elmer)
8.7.1 Business overview
8.7.2 Financial data
8.7.3 Product landscape
8.7.4 Strategic outlook
8.7.5 SWOT analysis
8.8 DIAsource ImmunoAssays SA
8.8.1 Business overview
8.8.2 Financial data
8.8.3 Product landscape
8.8.4 Strategic outlook
8.8.5 SWOT analysis
8.9 Hemagen Diagnostics
8.9.1 Business overview
8.9.2 Financial data
8.9.3 Product landscape
8.9.4 Strategic outlook
8.9.5 SWOT analysis
8.10 Trinity Biotech Plc.
8.10.1 Business overview
8.10.2 Financial data
8.10.3 Product landscape
8.10.4 Strategic outlook
8.10.5 SWOT analysis
8.11 SQI Diagnostics Inc.
8.11.1 Business overview
8.11.2 Financial data
8.11.3 Product landscape
8.11.4 Strategic outlook
8.11.5 SWOT analysis
8.12 Quest Diagnostics
8.12.1 Business overview
8.12.2 Financial data
8.12.3 Product landscape
8.12.4 Strategic outlook
8.12.5 SWOT analysis
8.13 Siemens Healthineers Inc.
8.13.1 Business overview
8.13.2 Financial data
8.13.3 Product landscape
8.13.4 Strategic outlook
8.13.5 SWOT analysis
